Loading...
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano, Raffaele Griffiths, Richard W Lorigan, Paul C Ashcroft, Linda Taylor, Paul Burt, Paul A Lee, Lip W Chittalia, Abbas Harris, Maggie A Faivre-Finn, Corinne
Califano, Raffaele
Griffiths, Richard W
Lorigan, Paul C
Ashcroft, Linda
Taylor, Paul
Burt, Paul A
Lee, Lip W
Chittalia, Abbas
Harris, Maggie A
Faivre-Finn, Corinne
Citations
Altmetric:
Abstract
The role of chemotherapy for advanced NSCLC patients and ECOG PS2 remains controversial. We evaluated 4 doses of 3-weekly docetaxel to identify a less toxic, clinically effective dose.
Description
Date
2011-09
Publisher
Keywords
Type
Article
Citation
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. 2011, 73 (3):338-44 Lung Cancer